X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MSP-2017 (etripamil) is a fast-acting, intranasally administered calcium-channel blocker, which is being evaluated for the treatment of Paroxysmal Supraventricular Tachycardia.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2024
Details:
Milestone intends to use the net proceeds from the Offering to continue the development of Cardamyst (etripamil) in its lead indication of paroxysmal supraventricular tachycardia.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Cardamyst
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Piper Sandler & Co
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 29, 2024
Details:
Milestone intends to use the net proceeds from the offering to continue the development of MSP-2017 (etripamil) in its lead indication of paroxysmal supraventricular tachycardia.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering February 28, 2024
Details:
MSP-2017 (etripamil) is a fast-acting, intranasally administered calcium-channel blocker, which is being evaluated for the treatment of Paroxysmal Supraventricular Tachycardia.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
MSP-2017 (etripamil) is a novel calcium channel blocker. It is under phase 3 clinical development for the treatment of paroxysmal supraventricular tachycardia.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 26, 2023
Details:
MSP-2017 (etripamil) is Milestone's lead investigational product. It is a novel calcium channel blocker nasal spray being developed for elevated and often highly symptomatic heart-rate attacks associated with PSVT and atrial fibrillation with a rapid ventricular rate.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
The net proceeds from the financing will be used to support the advancement of MSP-2017 (etripamil), a novel calcium channel blocker nasal spray, for paroxysmal supraventricular tachycardia.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: RTW Investments
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Financing March 28, 2023
Details:
MSP-2017 (etripamil) is a calcium channel antagonist potentially for the treatment of paroxysmal supraventricular tachycardia. It is designed to be a rapid-response therapy for elevated and often highly symptomatic heart rate attacks associated with PSVT and AFib-RVR.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
MSP-2017 (etripamil), a new chemical entity, is a novel calcium channel blocker designed to be a rapid-response therapy for episodic cardiovascular conditions.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Details:
MSP-2017 (etripamil), is a novel calcium channel blocker designed to be a rapid-response therapy for episodic cardiovascular conditions. As a nasal spray that is self-administered by the patient.
Lead Product(s): Etripamil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Medpace, Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
